Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.
Kim S, Vendrely V, Saint A, André T, Vaflard P, Samalin E, Pernot S, Bouché O, Zubir M, Desrame J, de la Fouchardière C, Smith D, Ghiringhelli F, Vienot A, Jacquin M, Klajer E, Nguyen T, François É, Taieb J, Le Malicot K, Vernerey D, Meurisse A, Borg C. Kim S, et al. Among authors: borg c. Exp Hematol Oncol. 2023 Jul 21;12(1):63. doi: 10.1186/s40164-023-00413-2. Exp Hematol Oncol. 2023. PMID: 37480095 Free PMC article.
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.
Ménard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taïeb J, Delahaye NF, Flament C, Emile JF, Le Cesne A, Zitvogel L. Ménard C, et al. Among authors: borg c. Cancer Res. 2009 Apr 15;69(8):3563-9. doi: 10.1158/0008-5472.CAN-08-3807. Epub 2009 Apr 7. Cancer Res. 2009. PMID: 19351841 Clinical Trial.
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY. Bennouna J, et al. Among authors: borg c. Clin Colorectal Cancer. 2012 Mar;11(1):38-44. doi: 10.1016/j.clcc.2011.05.002. Epub 2011 Jul 29. Clin Colorectal Cancer. 2012. PMID: 21803002 Clinical Trial.
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Among authors: borg c. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D, Lamfichekh N, Nerich V, Guiu B, Demarchi M, Borg C. Kim S, et al. Among authors: borg c. BMC Cancer. 2013 Dec 27;13:611. doi: 10.1186/1471-2407-13-611. BMC Cancer. 2013. PMID: 24373251 Free PMC article. Clinical Trial.
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Ghiringhelli F, Bichard D, Limat S, Lorgis V, Vincent J, Borg C, Berthou J, Orry D, Ortega-Deballon P, Lakkis Z, Facy O, Heyd B, Rat P, Nerich V, Ladoire S. Ghiringhelli F, et al. Among authors: borg c. Ann Surg Oncol. 2014 May;21(5):1632-40. doi: 10.1245/s10434-013-3463-y. Epub 2014 Jan 14. Ann Surg Oncol. 2014. PMID: 24419756 Free PMC article.
455 results